Docket Number:12A-931129
Inventor:Yuan-Tsong Chen, Jin-Jer Chen, Hsiang-Yu Yuan
IP Status:Issued TW334886、AU2005319028B2、CA2591840、EP1831402、HK1117571、IN245482、JP4516990、KR10-1178463、MX270342、NZ556461、SG133256、ZL200580048521.3
Abstract:
Warfarin is a common anticoagulant used for preventing thrombosis diseases, such as deep vein thrombosis, pulmonary embolism, ischemic heart diseases, valve replacement, and atrial fibrillation. The maintenance dose is widely variable among each individual. Overdose of warfarin may lead to serious bleeding while underdose may lead to increased risk of thrombosis and embolism. This invention was based on the finding that a functional promoter VKORC1 single nucleotide polymorphism (SNP) is associated with an individual's sensitivity to warfarin and can be used to predict the appropriate level of warfarin maintenance dose.
Fields of Application:
A pharmacogenetics-based warfarin dosing can be used for preventing thrombosis and embolism. The genetic markers (or SNP) described in the Invention can be used in identifying individuals who belonged to high, intermediate, or low warfarin dose groups. Such screening can be done prior to drug prescription or in the case of drug development and improve drug efficacy and lower bleeding risk.
Advantages when compared to the existing technologies:
None of the current method/technology has sufficient predictive value to be clinically useful in determining warfarin maintenance dosage before prescription.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
IP Status:Issued TW334886、AU2005319028B2、CA2591840、EP1831402、HK1117571、IN245482、JP4516990、KR10-1178463、MX270342、NZ556461、SG133256、ZL200580048521.3
